CN1219794C - 血小板糖蛋白受体阻抑物、含其的药物组合物及其用途 - Google Patents
血小板糖蛋白受体阻抑物、含其的药物组合物及其用途 Download PDFInfo
- Publication number
- CN1219794C CN1219794C CN 03112798 CN03112798A CN1219794C CN 1219794 C CN1219794 C CN 1219794C CN 03112798 CN03112798 CN 03112798 CN 03112798 A CN03112798 A CN 03112798A CN 1219794 C CN1219794 C CN 1219794C
- Authority
- CN
- China
- Prior art keywords
- receptor
- platelet
- compound
- composition containing
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 108091006082 receptor inhibitors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 14
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 206010061216 Infarction Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 abstract description 24
- 108020003175 receptors Proteins 0.000 abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 12
- 102000008946 Fibrinogen Human genes 0.000 abstract description 11
- 108010049003 Fibrinogen Proteins 0.000 abstract description 11
- 229940012952 fibrinogen Drugs 0.000 abstract description 11
- 229920001184 polypeptide Polymers 0.000 abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 abstract description 6
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 abstract description 6
- 230000004520 agglutination Effects 0.000 abstract description 2
- 210000001772 blood platelet Anatomy 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699802 Cricetulus griseus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- -1 antibody Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001723 fibrinogenic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229960002050 hydrofluoric acid Drugs 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 108010043943 Starch Phosphorylase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03112798 CN1219794C (zh) | 2003-01-30 | 2003-01-30 | 血小板糖蛋白受体阻抑物、含其的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03112798 CN1219794C (zh) | 2003-01-30 | 2003-01-30 | 血小板糖蛋白受体阻抑物、含其的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1434055A CN1434055A (zh) | 2003-08-06 |
CN1219794C true CN1219794C (zh) | 2005-09-21 |
Family
ID=27634151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03112798 Expired - Lifetime CN1219794C (zh) | 2003-01-30 | 2003-01-30 | 血小板糖蛋白受体阻抑物、含其的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1219794C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656616B (zh) * | 2012-08-31 | 2016-03-30 | 百奥泰生物科技(广州)有限公司 | 巴替非班注射剂及其制备 |
-
2003
- 2003-01-30 CN CN 03112798 patent/CN1219794C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1434055A (zh) | 2003-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6603149B2 (ja) | 心血管疾患を処置するためのニューレギュリン法および組成物 | |
KR100261898B1 (ko) | 환상유착 억제제 | |
DE69812630T2 (de) | Integrinbindendes peptid und dessen verwendung | |
JPH05500750A (ja) | 血小板凝集阻害剤 | |
US20130280273A1 (en) | Modulation of the Activity and Differentiation of Cells Expressing the Osteoclast-Associated Receptor | |
ATE366809T1 (de) | Addressine der schleimhaut und der blutgefässe und ihre verwendung | |
EP1740601A2 (en) | Myosin light chain kinase inhibitors and their use | |
CN102088999A (zh) | 用于治疗凝血细胞抑制剂诱导的凝血病的血管假性血友病因子或因子viii和血管假性血友病因子 | |
JP2006117633A (ja) | インターロイキン−8の模倣剤及び疾病の症状の予防、治療、診断及び改善におけるその使用方法 | |
WO1991011458A1 (en) | CYCLIC PEPTIDES CONTAINING Arg-Gly-Asp FLANKED BY PROLINE | |
JPH06184196A (ja) | ビトロネクチン由来合成ペプチドおよびそれらを含有する医薬組成物 | |
CA2122912A1 (en) | Novel peptides, and platelet aggregation-inhibiting agents, blood coagulation-inhibiting agents for extracorporeal circulation, cell adhesion-inhibiting agents, tumor metastasis inhibiting agents, agents for protecting platelet preparations for blood transfusion and platelet preparation packs for transfusion using said novel peptides | |
Lazarovici | Snake-and spider-venom-derived toxins as lead compounds for drug development | |
EP0655089A4 (en) | EFFECTS OF ACTIN FILAMENTS ON THE STRUCTURE AND LYSIS OF FIBRIN CLOTS. | |
JP5517387B2 (ja) | 活性化アンチトロンビンiiiを含有する医薬品 | |
CN1219794C (zh) | 血小板糖蛋白受体阻抑物、含其的药物组合物及其用途 | |
US5338725A (en) | Anti-aggregatory agents for platelets | |
CN102241735A (zh) | 用于预防及治疗急性冠脉综合症及抗凝抗血栓治疗的多肽及其应用 | |
KR20160087037A (ko) | 혈관석회화 방지용 조성물 및 이를 포함하는 혈관 석회화 치료제 | |
US7517654B2 (en) | Peptide and a derivative thereof promoting cell adhesion and spreading | |
Rinder et al. | Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation | |
EP0333517A2 (en) | Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor | |
US6413931B1 (en) | Peptide inhibitor of fibrinogen blood clotting | |
EP3333177B1 (en) | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof | |
CA3145703A1 (en) | A peptoid-peptide hybrid, nmeg-acgrp, and its use in cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BIOTHERA SOLUTIONS LTD. Free format text: FORMER OWNER: GUAN YUCHAN Effective date: 20110113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110113 Address after: 510760, No. 63, Po Po Industrial Road, Whampoa District, Guangdong, Guangzhou Patentee after: Bio-Thera Solutions, Ltd. Address before: 510760, No. 63, Po Po Industrial Road, Whampoa District, Guangdong, Guangzhou Patentee before: Guan Yuchan |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Shengfeng Inventor before: Li Shengfeng |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 510000 Guangzhou Hi-tech Industrial Development Zone, Guangdong Province, Fifth Floor, Building A6, 11 Kaiyuan Avenue, Science City Patentee after: BIO-THERA SOLUTIONS, Ltd. Address before: 510760 No. 63 Yunpu Industrial Pu South Road, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Bio-Thera Solutions, Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050921 |